Votrient pazopanib: Preliminary Phase II data

Researchers at the Fondazione IRCCS Istituto Nazionale dei Tumori reported preliminary data from 18 patients in an ongoing, open-label, Italian Phase II trial showing that once-daily 800 mg oral pazop...